louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00487357: MATCh Parents' Supplemental Survey
Official title: MATCh Parents' Supplemental Survey: Predictors of Smoking in Mexican American Youth
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epidemiology
Keywords: Epidemiology
Cancer Prevention
Questionnaire
MATCh
Survey
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
First posted: 2007-06-18
Enrollment: 1215
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Parents/guardians of participants in the MATCh study (accompany UT MDACC Protocol 2004-0616, "Predictors of Smoking in Mexican American Youth," also known as the MATCh study).

Brief summary: Primary Objectives:

1. To collect data on health behaviors in the parents of MATCh study participants
2. To collect and/or update risk factor data from the parents of the MATCh study participants.

Detailed description: This research project is for the parents of study participants in the "Predictors of Smoking in Mexican American Youth," also known as the MATCh study.

This research project has three objectives.

These include:

1. collecting data on your health behaviors. Researchers are interested in this information because your health behaviors may influence your children's health behavior;
2. learning about the types of interventions that would be of most use and interest to you and your family; and
3. learning about the most convenient and useful way in which these interventions would be delivered.

Researchers are interested in knowing about the types of interventions that would benefit you and your family because they would like to design future intervention studies that meet your needs and the needs others in your community.

Eligibility criteria: Inclusion Criteria:

1. The parent or legal guardian of the child participating in UT MDACC Protocol 2004-0616. Parents/legal guardians will be identified and enrolled after their child is enrolled in protocol 2004-0616.
2. Participants who speak English, Spanish or are bilingual are eligible to participate.

Exclusion Criteria: None

Primary outcomes:
measure: Data collection on health behaviors in the parents of MATCh study participants.
timeFrame: 4 Years
Secondary outcomes:
measure: Data collection and/or update risk factors from the parents of the MATCh study participants.
timeFrame: 4 Years
Other outcomes:
Locations:
city: Houston
country: United States
facility: UT MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Sara Strom, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06225557: Comparison of Outcome Between (ERACS) Versus Traditional Methods in Elective CS
Official title: Comparison of Outcome Between the Implementation of Enhanced Recovery After Elective Cesarean Section Protocol (ERACS) Versus Traditional Methods
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: ERAS
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2024-01-26
Enrollment: 106
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: follow ERAS society guidelines recommendations in elective CESAREAN SECTION
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The study is designed to evaluate the effect of implementing enhanced recovery after surgery (ERAS) protocol during elective cesarean section on patient's outcome measures.

Detailed description: The study is designed to evaluate the effect of implementing enhanced recovery after surgery (ERAS) protocol during elective cesarean section on patient outcome measures. The primary outcome is the evaluation of inpatient postpartum recovery using the Obstetric Quality of Recovery 11 score (ObsQoR-11) at the time of discharge.

Secondary outcomes are the evaluation of peak numeric postoperative pain rating score within the postoperative hospital stay, total amount of postoperative opioid consumption, postoperative nausea, and vomiting impact score after 6 hours postoperatively and at time of discharge, patient satisfaction using Leiden perioperative care patient satisfaction questionnaire (LPPSq) at time of discharge, presence of post-cesarean ileus and Hospital length to achieve criteria for discharge.

Eligibility criteria: Inclusion Criteria:

* Pregnant women ASA I to ASA II aged from 18 up to 40 years. With non-complicated pregnancy undergoing elective CS.

Exclusion Criteria:

* -Age less than 18 years
* Complications (wound infection, re-exploration, caesarean hysterectomies)
* Recent documented use of opioids Allergy to any drug used during the study.-
* Patients with severe heart diseases, cardiac arrhythmia and myocardial injury.
* uncontrolled diabetic patient
* Severe liver and kidney diseases
* Coagulation defect

Primary outcomes:
measure: Obstetric Quality of Recovery 11 score (ObsQoR-11)
timeFrame: before discharge or during 24 hour postoperatively
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Faculty of Medicine, Minia University
name: Ahmad EZ Mahran, professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03658057: Measurement of the Skin Sympathetic Nerve Activity
Official title: Recording Sympathetic Nerve Activity From the Skin During Surgery Under General Anesthesia : a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Skin Sympathetic Nerve Activity During General Anesthesia in Patients Undergoing Breast Cancer Surgery
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2018-09-05
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Sympathetic nerve activity can be measured transcutaneously in awake patients by computer-based filtering of raw signal obtained via skin leads attached on the chest. Electrocardiogram can be removed by applying a high-pass filter setting of 150 Hz. Electromyogram can be filtered by applying a high-pass filter setting of 500 Hz or a band-pass filter setting of 500-1000 Hz.

However, it is not known whether the skin sympathetic nerve activity (SKNA) can be measured in anesthetized and/or paralyzed patients. Therefore, we planned this pilot study to observe whether the SKNA can be obtained in these patients. If the SKNA ca be observed, it will be presented in milivolt (uV).


Eligibility criteria: Inclusion Criteria:

* patients scheduled to undergo resection of breast cancer under general anesthesia after insertion of laryngeal mask airway

Exclusion Criteria:

* Autonomic nervous system disease
* Medication acting on the autonomic nervous system
* Refuse to participate

Primary outcomes:
measure: The skin sympathetic nerve activity presented as uV obtained via skin leads.
timeFrame: During surgery/anesthesia
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Yunseok Jeon, Jeon
role: STUDY_DIRECTOR
References:
Clinical trial NCT04252157: Taping for Saliva Control in Cerebral Palsy
Official title: The Effect of Kinesiotaping on Saliva Control in Children With Cerebral Palsy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cerebral Palsy
Keywords: saliva
taping
Lead sponsor: Baskent University
Sponsor class: OTHER
First posted: 2020-02-05
Enrollment: 45
Sex: ALL
Minimum age (years): 5
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aim to investigate the effect of banding on saliva control and quality of life in children with cerebral palsy.

Detailed description: Cerebral palsy describes a whole set of permanent disorders or disorders in the development of movement and posture, attributed to non-progressive disorders occurring in the developing fetal or infant brain, causing activity limitation. Motor disorders are often accompanied by sensory, perception, communication and behavioral disorders, epilepsy and secondary musculoskeletal problems.

Kinesio Taping has been proven to increase local circulation, reduce local edema and provide a positional stimulus for muscle, skin, or facial structures, regulating sensory input, and activating regions in the brain. KT is currently used to improve oral control in children with neurological and neuromuscular disorders and provides a reduction in saliva flow and frequency. However, knowledge of the potential of using neuromuscular bandages to manage the dribble flow has been limited.

Eligibility criteria: Inclusion Criteria:

* Being a dribble control disorder,
* Having a diagnosis of cerebral palsy,
* Being between the ages of 5-15,
* Not allergic to Kinesio Taping tape.

Exclusion Criteria:

* Using drugs for saliva control disorder,
* Botulinum toxin has been applied in the last 6 months,
* Active infection (tooth, intestine, etc.),
* Failure to comply with treatment,
* Swallowing disorder.

Primary outcomes:
measure: Sociodemographic Features
timeFrame: baseline
measure: Saliva Flow Amount
timeFrame: 2 days after taping
measure: Intensity and Frequency of Dribble Flow
timeFrame: 2 days after taping
Secondary outcomes:
measure: Posture Evaluation
timeFrame: 2 days after taping
measure: Evaluation of the Effect on Family
timeFrame: 2 days after taping
measure: The Gross Motor Function Classification System Assesment
timeFrame: 2 days after taping
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Aydan
Study officials:
References:
Clinical trial NCT06707857: Effects of TNT on Pain, ROM and Disability in Patients With RC Tendinopathy
Official title: Effects of Tendon Neuroplastic Training on Pain, Range of Motion and Disability in Patients With Rotator Cuff Tendinopathy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Rotator Cuff Tendinopathy
Keywords: Rotator cuff tendiopathy
Tendon neuroplastic training
Disability
Range of motion
Pain
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2024-11-27
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: In this parallel- group randomized control trial(RCT) Rotator cuff tendinopathy patients will be assigned to either tendon neuroplastic training or to traditional treatment plan. this study aims to evaluate the effects pf tendon neuroplastic training on pain, range of motion and disability.
Primary purpose: TREATMENT

Brief summary: EFFECTS OF TENDON NEUROPLASTIC TRAINING ON PAIN, RANGE OF MOTION AND DISABILITY IN PATIENTS WITH ROTATOR CUFF TENDINOPATHY

Detailed description: Rotator cuff tendinopathy is a condition where the shoulder's tendon suffers small tears or inflammation, often causing pain frequently arises from repetitive overuse or the natural aging process Regular overhead activities can aggravate the shoulder's wear and tear, leading to tendinosis. The purpose of this study is to evaluate and compare the impact of tendon neuroplastic training with standard treatments on pain levels, functional disability, and the range of motion in patients suffering from rotator cuff tendinopathy. Data were collected from Riphah rehabilitation clinic Lahore. Nprs , goinmeter and Spadi questioner were used before and after the intervention. Assessment was done through the tool before and after the treatment.

Eligibility criteria: Inclusion Criteria:

* Have a current shoulder complaint lasting at least three months prior to the time of enrollment
* Pain is located in the proximal lateral aspect of the upper arm (C5 dermatome)
* Positive Hawkins-Kennedy test

Exclusion Criteria:

* Bilateral shoulder pain
* Less than 90 degrees of active elevation of the arm
* Corticosteroid injection within the last six weeks
* Radiologically verified fracture
* Glenohumeral osteoarthritis
* Surgery or dislocation of the affected shoulder
* Symptomatic arthritis in the Ac joint
* Frozen shoulder
* Symptoms derived from the cervical spine

Primary outcomes:
measure: Numeric pain rate scale (NPRS)
timeFrame: 6 weeks
measure: Shoulder pain and disability index (spadi)
timeFrame: 6 weeks
measure: Universal Goniometer (UG)
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Riphah Rehabilitation clinic
state: Punjab
Study officials:
affiliation: Riphah International University
name: Saba Rafique, MS-OMPT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04792957: JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
Official title: Expression of the JAK-STAT Signaling Pathway in Pyoderma Gangrenosum Pathological Biopsy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pyoderma Gangrenosum
Hidradenitis Suppurativa
Psoriasis
Keywords: JAK-STAT pathway
Pyoderma Gangrenosum
Skin Biopsy
Lead sponsor: Dokuz Eylul University
Sponsor class: OTHER
First posted: 2021-03-11
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients from İzmir Katip Çelebi University, Ataturk Education and Research Hospital Department of Rheumatology

Brief summary: The investigators hypothese that Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway play a key role in pathophysiology of pyoderma gangrenosum (PG). In this study JAK/STAT signaling pathway will be investigated in the skin biopsies of PG patients

Detailed description: Cytokines are key molecules in the pathogenesis of inflammatory diseases. These molecules exert their effects through cell surface receptors and intracellular signaling pathways. Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway is implicated in the pathogenesis of several autoimmune diseases. Pyoderma gangrenosum (PG) is an inflammatory skin disease characterized by progressive and recurrent skin ulceration of destructive course. Treatment of PG requires aggressive immunosuppressive therapy but despite the use of several agents, including tumor necrosis factor inhibitory treatments there is still an unmet need in refractory PG. Recent reports suggested activation of JAK/STAT pathway in PG and some case-based studies suggested the beneficial effect of JAK-STAT inhibitory agent in the treatment of PG.

Skin biopsies obtained from PG, hidradenitis suppurativa, psoriasis and healthy subjects will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods. The following immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining intensity will be recorded categorically (negative and positive). The positive staining will also be graded semi-quantitively as follows: mildly positive, moderately positive and strongly positive.

Eligibility criteria: Inclusion Criteria:

* Pyoderma gangrenosum diagnosed with skin biopsy
* Psoriasis diagnosed with skin biopsy
* Hidradenitis suppurativa diagnosed with skin biopsy
* Skin biopsy in healthy subjects

Exclusion Criteria:

- This is a case-based study and there is no exclusion criteria

Primary outcomes:
measure: Expression of JAK-STAT pathway
timeFrame: 15 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02098057: Change in Permeability of the Small Intestine After Treatment With Gluten
Official title: A Pilot Study Barrier Function, Intestinal Permeability and Tight Junction Expression in Gluten Sensitive Patients With Functional Gastrointestinal Disorders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gastrointestinal Disorders
Keywords: IBS-diarrhea
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2014-03-27
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The overall hypothesis of this research study is that gluten intake alters intestinal barrier function in patients with Irritable Bowel Syndrome (IBS) diarrhea who also exhibit non-celiac gluten sensitivity (NCGS).

Detailed description: The specific aim of this hypothesis-generating, pilot study is to randomize (like the flip of a coin) patients who have Non Celiac Gluten Sensitivity to a 4-week Gluten-containing diet (GCD) or to a Gluten free diet (GFD). The study will evaluate small bowel (SB) permeability functionally (2-sugar differential excretion), morphologically, using probe-based confocal laser to evaluate the small intestinal, as well as molecularly, using tight junction (TJ) messenger RNA (mRNA) expression in small bowel mucosa in response to the different diets.

Eligibility criteria: Inclusion Criteria:

1. Non celiac gluten sensitive patients with a functional bowel disorder
2. Age 18 to 70 years.

Exclusion Criteria:

1. Positive serum tissue transglutaminase (TTG) Immunoglobulin A (IgA) positive or medical record of small bowel biopsy suggestive of celiac disease.
2. Use of tobacco products within the past 6 months (since nicotine may affect intestinal permeability).
3. Abdominal surgeries (except appendectomy, cholecystectomy and vaginal hysterectomy or tubal ligation)
4. Use of Nonsteroidal Anti-inflammatory Drugs(NSAIDs) or aspirin within the past week (since Nonsteroidal Anti-inflammatory Drugs (NSAIDs) affect intestinal permeability).
5. Use of oral corticosteroids within the previous 6 weeks.
6. Ingestion of artificial sweeteners such as Sucralose, Nutrasweet ™ (aspartame), lactulose or mannitol 2 days before the study tests begins, e.g., foods to be avoided are sugarless gums or mints and diet soda.
7. Bleeding disorders or medications that increase risk of bleeding from mucosal biopsies.
8. High anxiety or depression score (\>11 on each subscale) on the Hospital Anxiety Depression Score questionnaire.
9. Known allergy to fluorescein.

Primary outcomes:
measure: Change in permeability of the small intestine after treatment
timeFrame: Baseline to 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Maria I Vazquez Roque, MD, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02471157: Hormonal Predictors of Oncologic Surgery
Official title: The Association of Hypogonadism and Post-operative Outcomes of Oncologic Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypogonadism
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
First posted: 2015-06-15
Enrollment: 200
Sex: MALE
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Men undergoing renal, bladder, and colorectal surgery for cancer

Brief summary: An observational trial to determine whether preoperative hormonal status predicts outcomes of oncologic surgery.


Eligibility criteria: Inclusion Criteria:

* Undergoing above surgery for cancer

Exclusion Criteria:

* Started hormonal replacement in past two months

Primary outcomes:
measure: Length of Stay
timeFrame: 6 days, on average
measure: Complication rate, post-operative
timeFrame: 6 days, on average
measure: Complication rate, 30 day
timeFrame: 30 days
measure: Complication rate, 90 days
timeFrame: 90 days
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Weill Cornell Medical College
state: New York
Study officials:
affiliation: Weill Medical College of Cornell University
name: Douglas Scherr, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05025657: Advocates for All Youth
Official title: Advocates for All Youth
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Depression, Anxiety
Self Efficacy
Suicidal Ideation
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2021-08-27
Enrollment: 1000
Sex: ALL
Minimum age (years): 9
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Advocates for ALLY Youth (ALLY) is a universal, school-based, multicomponent positive psychology program aimed to increase youth's well-being and reduce symptoms of psychological distress including depression, anxiety, and stress.


Eligibility criteria: Inclusion Criteria:

* students enrolled at participating schools

Exclusion Criteria:

* none

Primary outcomes:
measure: Symptoms of Anxiety and Depression
timeFrame: 3 months
Secondary outcomes:
measure: Self-efficacy
timeFrame: 3 months
Other outcomes:
Locations:
city: Loachapoka
country: United States
facility: Loachapoka Elementary School
state: Alabama
Study officials:
References: